Burns T A, Dembek K A, Kamr A, Dooley S B, Dunbar L K, Aarnes T K, Bednarski L S, O'Brien C, Lakritz J, Byrum B, Wade A, Farmer R, Tan S, Toribio R E
The Ohio State University College of Veterinary Medicine, Columbus, OH.
Consumer Protection Laboratory, Analytical Toxicology Section, Ohio Department of Agriculture, Reynoldsburg, OH.
J Vet Intern Med. 2018 Jan;32(1):441-449. doi: 10.1111/jvim.15029. Epub 2017 Dec 29.
Cobalt chloride (CoCl ) is administered to racehorses to enhance performance. The purpose of this study was to evaluate the clinical, cardiovascular, and endocrine effects of parenterally administered CoCl .
To describe the effects of weekly intravenous doses of CoCl on Standardbred horses.
Five, healthy Standardbred mares.
Prospective, randomized, experimental dose-escalation pilot. Five Standardbred mares were assigned to receive 1 of 5 doses of CoCl (4, 2, 1, 0.5, or 0.25 mg/kg) weekly IV for 5 weeks. Physical examination, blood pressure, cardiac output, and electrocardiography (ECG) were evaluated for 4 hours after administration of the first and fifth doses. Blood and urine samples were collected for evaluation of cobalt concentration, CBC and clinical chemistry, and hormone concentrations.
All mares displayed pawing, nostril flaring, muscle tremors, and straining after CoCl infusion. Mares receiving 4, 2, or 1 mg/kg doses developed tachycardia after dosing (HR 60-126 bpm). Ventricular tachycardia was noted for 10 minutes after administration of the 4 mg/kg dose. Increases in systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) occurred after administration of all doses (4, 2, 1, 0.5, and 0.25 mg/kg). Profound hypertension was observed after the 4 mg/kg dose (SAP/DAP, MAP [mmHg] = 291-300/163-213, 218-279). Hemodynamics normalized by 1-2 hours after administration. ACTH and cortisol concentrations increased within 30 minutes of administration of all CoCl doses, and cardiac troponin I concentration increased after administration of the 4 and 2 mg/kg doses.
The degree of hypertension and arrhythmia observed after IV CoCl administration raises animal welfare and human safety concerns.
氯化钴(CoCl)被用于赛马以提高其性能。本研究的目的是评估经肠胃外给予氯化钴后的临床、心血管和内分泌效应。
描述每周静脉注射氯化钴对标准赛马的影响。
五匹健康的标准赛马母马。
前瞻性、随机、实验性剂量递增试验。五匹标准赛马母马被分配接受五剂氯化钴(4、2、1、0.5或0.25毫克/千克)中的一剂,每周静脉注射一次,共5周。在首次和第五次给药后4小时评估体格检查、血压、心输出量和心电图(ECG)。采集血液和尿液样本以评估钴浓度、全血细胞计数和临床化学以及激素浓度。
所有母马在输注氯化钴后均出现刨地、鼻孔扩张、肌肉震颤和用力。接受4、2或1毫克/千克剂量的母马在给药后出现心动过速(心率60 - 126次/分钟)。在给予4毫克/千克剂量后10分钟内记录到室性心动过速。所有剂量(4、2、1、0.5和0.25毫克/千克)给药后收缩压(SAP)、舒张压(DAP)和平均动脉压(MAP)均升高。在给予4毫克/千克剂量后观察到严重高血压(SAP/DAP,MAP[毫米汞柱]=291 - 300/163 - 213,218 - 279)。给药后1 - 2小时血流动力学恢复正常。所有氯化钴剂量给药后30分钟内促肾上腺皮质激素(ACTH)和皮质醇浓度升高,4和2毫克/千克剂量给药后心肌肌钙蛋白I浓度升高。
静脉注射氯化钴后观察到的高血压和心律失常程度引发了对动物福利和人类安全的担忧。